Glycoimmunomics of human cancer: Current concepts and future perspectives

Future Oncology

Volumn 3, Issue 2, 2007, Pages 201-214

  Ravindranath, Mepur H ^a   Yesowitch, Paul ^a   Sumobay, Cindy ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Antigen presentation; CD1; Colon cancer; Gangliosides; Glycoantigens; Glycoimmunomics; Glycolipids; Glycomics; Glycoproteins; Immunoglobulin; Immunosuppression; M antibodies; Melanoma; Natural killer T cells; O linked and N linked oligosaccharides; Ovarian cancer; Prostate cancer; Renal carcinoma; Sarcoma; Siglec

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; CERAMIDE; FATTY ACID; FUCOSE; GALACTOSE; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; GLUCOSE; GLYCOLIPID; GLYCOPROTEIN; LIPID; MANNOSE; N ACETYLGALACTOSAMINE; N ACETYLGLUCOSAMINE; N ACETYLNEURAMINIC ACID; N GLYCOLOYLNEURAMINIC ACID; OLIGOSACCHARIDE; PEPTIDE; SUGAR;

ANTIBODY TITER; B LYMPHOCYTE; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER INCIDENCE; CLINICAL PROTOCOL; COLORECTAL CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOBIOLOGY; HUMAN; IMMUNOCOMPETENCE; IMMUNOGENICITY; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN STRUCTURE; REVIEW; SARCOMA; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; GLYCOLIPIDS; GLYCOPROTEINS; HUMANS; NEOPLASMS; TUMOR STEM CELLS;

EID: 34247188629     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.2.201     Document Type: Review

References (58)

1. Morton DL, Ollila DW, Hsueh EC, Essner R, Gupta RK: Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J. Clin. 49, 101-116 (1999).
2. Grichnik JM, Burch JA, Schulteis RD et al. Melanoma, a tumor based on a mutant stem cell? J. Invest. Dermatol. 126, 142-153 (2006).
3. Lacroix M: Significance, detection and markers of disseminated breast cancer cells. Endocr. Relat. Cancer 13, 1033-1067 (2006).
4. Balic M, Lin H, Young L et al.: Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12, 5615-5621 (2006).
5. Wilson MT, Singh AK, van Kaer L: Immunotherapy with ligands of natural killer T cells. Trends Mol. Med. 8, 225-231 (2002).
6. Young DC, Moody DB: 2006 T-cell recognition of glycolipids presented by CD1 proteins. Glycobiology 16, 103R-112R (2006).
7. Brutkiewicz RR: CD1d Ligands: the good, the bad, and the ugly. J. Immunol. 177, 769-775 (2006).
8. Angata T, Varki A: Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of Siglecs. Evidence for co-evolution with sialic acid synthesis pathways. J. Biol. Chem. 275, 22127-22135 (2000).
9. Rapoport E, Mikhalyov I, Zhang J, Crocker P, Bovin N: Ganglioside binding pattern of CD33-related siglecs. Bioorg. Med. Chem. Lett. 13, 675-678 (2003).
10. Nicoll G, Avril T, Lock K, Furukawa K, Bovin N, Crocker PR: Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via Siglec-7-dependent and -independent mechanism. Fur. J. Immunol. 33, 1642-1648 (203).
11. Ikehara Y, Ikehara SK, Paulson JC: Negative Regulation of T Cell Receptor Signaling by Siglec-7 (p70/AIRM) and Siglec-9 J. Biol. Chem. 279, 43117-43125 (2004).
12. Ravindranath MH, Morton DL. Antigens: carbohydrates. In: Ecyclopedia of Life Sciences. MacMillan. Co. London, UK (2000).
13. Berger EG, Buddecke E, Kamerling JP, Kobata A, Paulson JC, Vliegenthart JF: Structure, biosynthesis and functions of glycoprotein glycans. Experientia 38, 1129-1162 (1982).
14. Wiegandt H: Gangliosides. In: Glsycolipids. Elsevier Science Publishers, Amsterdam Williams, 1-68 (1985).
15. Basu M, De T, Das KK et al.: Glycolipids. Methods Enzymol. 138, 575-607 (1987).
16. Kleene R, Berger EG: The molecular and cell biology of glycosyltransferases. Biochim. Biophys. Acta. 1154, 283-325 (1993).
17. Rich MR, Evans JS: Molecular dynamics simulations of adipocyte lipid-binding protein: effect of electrostatics and acyl chain unsaturation. Biochemistry 35, 1506-1515 (1996).
18. Mond JJ, Lees A, Snapper CM: T cell-independent antigens type 2. Annu. Rev. Immunol. 13, 655-692 (1995).
19. Brewer JW, Randall TD, Parkhouse RM, Corley RB: IgM hexamers. Immunol. Today 15, 165-168 (1994).
20. Davis AC, Roux KH, Shulman MJ: On the structure of IgM. Eur. J. Immunol. 18, 1001-1008 (1998).
21. Randall TD, King LB, Corley RB: The biological effects of IgM hexamer formation. Eur. J. Immunol. 20, 1971-1979 (1990).
22. Randall TD, Parkhouse RM, Corley RB: J-chain synthesis and secretion of hexameric IgM is differentially regulated by lipopolysaccharide and interleukin 5. Proc. Natl Acad. Sci. USA 89, 962-966 (1992).
23. +B oells. Cell Mol. Life Sci. 53, 750-758 (1997).
24. Ravindranath MH, Ravindranath RM, Morton DI, Graves MC: Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA. J. Immunol. Methods 169, 257-272 (1994).
25. Ravindranath MH, Muthugounder S, Saravanan TS, Presser N, Morton DL: Human antiganglioside antoantibodies: validation of ELISA. Ann. N Y Acad. Sci. 1050, 229-242 (2005).
26. Ravindranath MH, Gonzales AM, Nishimoto K, Tam WY, Soh D, Morton DL: Immunology of gangliosides. Indian J. Exp. Biol. 38, 301-312 (2000).
27. Perez CA, Ravindranath MH, Soh D, Gonzales A, Ye W, Morton DL: Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J. 8, 384-394 (2002).
28. Ravindranath MH, Wood TF, Soh D et al.: Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM. Cryobiology 45, 10-21 (2002).
29. Bogoch S: Demonstration of serum precipitin to brain ganglioside. Nature 185, 392-393 (1960).
30. Rapport MM, Graf L: Immunochemical reactions of lipids. Prog. Allergy 13, 273-331 (1969).
31. Sherwin AL, Lowden JA, Wolfe LS: The production of antisera to gangliosides from human nervous tissue. Can. J. Biochem. Physiol. 42, 1640-1643 (1964).
32. Pascal TA, Saifer A, Gitlin J: Immunochemical studies on normal and Tay-Sachs' brain gangliosides. Proc. Soc. Exp. Biol. Med. 121, 739-743 (1966).
33. Koscielak J, Hakomori S, Jeanloz RW: Glycolipid antigen and its antibody. Immunochemistry 5, 441-455 (1968).
34. Naiki M, Marcus DM, Ledeen R: Properties of antisera to ganglioside GM1 and asialo GM1. J. Immunol. 113, 84-93 (1974).
35. Yokoyama M, Trams EG, Brady RO: Immunochemical studies with gangliosides. Immunol. 90, 372-380 (1963).
36. Helling F, Calves M, Shang Y, Oettgen HF, Livingston PO: Construction of immunogenic GD3-conjugate vaccines. Ann. N Y Acad. Sci. 690, 396-397 (1993).
37. Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oettgen HF, Old LJ: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. USA 84, 2911-2915 (1987).
38. Gillard BK, Thomas JW, Nell LJ, Marcus DM: Antibodies against ganglioside GT3 in the sera of patients with Type I diabetes mellitus. J. Immunol. 142, 3826-3832 (1989).
39. Ravindranath MH, Bauer PM, Amiri AA et al.: Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Le(a), sialyl Le(x), GD3 and GM2) better than soluble lysate cancer vaccine. Anticancer Drugs 8, 217-224 (1997).
40. Ravindranath MH, Morton DL, Irie RF: Attachment of monophosphoryl lipid A (MPL) to cells and liposomes augments antibody response to membrane-bound gangliosides. J. Autoimmun. 7, 803-816 (1994).
41. Ravindranath MH, Morton DL: Immunogenecity of membrane-bound gangliosides in viable whole-cell vaccines. Cancer Invest. 15, 491-499 (1997).
42. Ando I, Hoon DS, Suzuki Y, Saxton RE, Golub SH, Irie RF: Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells. Int. J. Cancer (Erratum in: Int. J. Cancer) 40, 12-17 (1987).
43. Hoon DS, Ando I, Sviland G et al.: Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells. Int. J. Cancer 43, 857-862 (1989).
44. Grayson G. Ludisch S: Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity. Cell Immunol. 139, 18-29 (1992).
45. Kanda N: Gangliosides GD1a and GM3 induce interleukin-10 production by human T cells. Biochem. Biophys. Res. Commun. 256, 41-44 (1999).
46. Prokazova NV, Dyatlovitskaya EV, Bergelson LD: Sialylated lactosylceramides. Possible induces of non-specific immunosuppression and atherosclerotic lesions. Eur. J. Biochem. 172, 1-6 (1998).
47. Prokazova NV, Bergelson LD: Gangliosides and atherosclerosis. Lipids 29, 1-5 (1994).
48. Kanda N, Watanabe S: Gangliosides GD1a enhances immunoglobulin production by human peripheral blood monoclear cells. Exp. Hematol. 28, 672-679 (2000).
49. Ravindranath MH, Gonzales A, Soh D et al.: Interleukin-2 binds to ganglioside GD(1b). Biochem. Biophys. Res. Commun. 283, 369-373 (2001)
50. Kanda N, Tamaki K: Ganglioside GD1b suppresses immunoglobulin production by human peripheral blood mononuclear cells. Exp. Hematol. 27, 1487-1493 (1999).
51. Kanda N, Watanabe S: Gangliosides GD1b, GT1b, and GQ1b enhance IL-2 and IFN-γ production and suppress IL-4 and IL-5 production in phytohemagglutinin-stimulated human T cells. J. Immunol. 166, 72-80 (2001).
52. Thornton MV, Kudo D, Rayman P et al.: Degradation of NF-κB in T cells by gangliosides expressed on renal cell carcinomas. J. Immunol. 172, 3480-3490 (2004).
53. Biswa K, Richmond A, Rayman P et al.: GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res. 66, 6816-25 (2006).
54. Ravindranath MH, Hsueh EC, Verma M. Ye W, Morton DL: Serum total ganglioside level correlates with clinical course in melanoma patients after immunotherapy with therapeutic cancer vaccine. J. Immunother. 26, 277-285 (2003).
55. Ravindranath MH, Muthugounder S, Presser N et al.: Gangliosides of organ-confined versus metastatic androgen-receptor-negative prostate cancer Biochem. Biophys. Res. Commun. 324, 154-465 (2004).
56. Ravindranath MH, Muthugounder S, Presser N, Ye X, Brosman S, Morton DL: Endogenous immune response to gangliosides in patients with confined prostate cancer. Int. J. Cancer 116, 368-377 (2005).
57. Ravindranath MH, Muthugounder S, Presser N et al.: Immunogenic gangliosides in human ovarian carcinoma. Biochem. Biophys. Res. Commun. 353, 251-258 (2007).
58. Nudelman E, Hakomori S, Kannagi R et al.: Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2. J. Biol. Chem. 257, 12752-12756 (1982).